A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease

Inclusion Criteria 1. Male or female subjects at least 30 years old; 2. Subjects with advanced Parkinson's disease who are already on LCIG (Duodopa®) for at least 30 days; 3. Body mass index range from 18.0 to 30.0 kg/m2 Exclusion Criteria 1. Subjects who are considered to be violent or subjects considered at suicidal risk by the investigator; 2. Clinically significant abnormal laboratory data at baseline or any abnormal laboratory value that could interfere with the study assessments; 3. Subjects with serious symptomatic cerebral disease, cerebrovascular disease, focal neurological lesions (previous brain surgery), any acute brain trauma requiring treatment with anticonvulsant therapy, or acute stroke